Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey

Craig M. Hales; Qiuping Gu; Cynthia L. Ogden; Susan Z. Yanovski

doi:10.1002/oby.23299

journal article Dec 14, 2021

Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey

Craig M. Hales

Qiuping Gu Cynthia L. Ogden

Susan Z. Yanovski

Obesity Vol. 30 No. 1 pp. 229-239 · Wiley

View at Publisher Save 10.1002/oby.23299

Abstract

AbstractObjectiveThis study aimed to evaluate trends in the use of obesogenic medications among adults.MethodsCross‐sectional data on adults aged ≥20 years are from the 1999 to 2018 National Health and Nutrition Examination Survey (n = 52,340). Obesogenic medications were defined according to the 2015 Endocrine Society guidelines on the pharmacological management of obesity. Weight status was categorized according to BMI. Trends in prior 30‐day use were evaluated.ResultsIn NHANES 2017‐2018, 20.3% of US adults used an obesogenic medication. Beta‐blockers (9.8%) and antidiabetics (5.7%) were the most common; antipsychotics (1.0%) were the least common. Most common indications were disorders of glucose metabolism, hypertension, neuralgia or neuritis, heart disease, and musculoskeletal pain and/or inflammation. From 1999 to 2018, the proportional use of obesogenic medications increased for anticonvulsants (34.4% to 55.0%) but decreased for antidepressants (32.1% to 18.8%), antidiabetics (82.9% to 52.5%), and beta‐blockers (83.9% to 80.7%). The proportional use of obesogenic medications was not associated with weight status, except for antipsychotics.ConclusionsUse of obesogenic medications was common. Differences in the proportional use of obesogenic medication may reflect changing availability of obesogenic versus nonobesogenic medications over time. The decision to prescribe a nonobesogenic alternative, if one exists, is guided by weighing the risks and benefits of available treatments.

Topics

No keywords indexed for this article. Browse by subject →

References

41

[1]

FryarCD CarrollMD OgdenCL.Prevalence of overweight obesity and severe obesity among adults aged 20 and Over: United States 1960‐1962 through 2015‐2016.Health E‐Stats. National Center for Health Statistics;2018.

[2]

Hales CM "Prevalence of obesity and severe obesity among adults: United States, 2017‐2018" NCHS Data Brief (2020)

[3]

Centers for Disease Control and Prevention. Adult obesity causes & consequences. Updated March 22 2021. Accessed April 12 2021.https://www.cdc.gov/obesity/adult/causes.html

[4]

10.1002/oby.22444

[5]

10.1038/s41366-018-0207-x

[6]

10.1210/jc.2014-3415

[7]

10.1002/oby.22903

[8]

10.1001/jama.2015.13766

[9]

10.1016/j.annepidem.2011.10.010

[10]

ChenTC ClarkJ RiddlesMK MohadjerLK FakhouriTHI.National Health and Nutrition Examination Survey 2015‐2018: Sample design and estimation procedures: data evaluation and methods research. Vital and Health Statistics series 2 no. 184. National Center for Health Statistics; 2020.

[11]

Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey 1988‐2018 data documentation codebook and frequencies: prescription medications ‐ drug information (RXQ_DRUG). Published August 2007. Updated September 2021. Accessed April 12 2021.https://wwwn.cdc.gov/Nchs/Nhanes/1999‐2000/RXQ_DRUG.htm

[12]

Centers for Disease Control and Prevention.National Health and Nutrition Examination Survey 2017‐2018 data documentation codebook and frequencies: prescription medications(RXQ_RX_J). Published March 2020.https://wwwn.cdc.gov/Nchs/Nhanes/2017‐2018/RXQ_RX_J.htm

[13]

10.1210/jc.2014-3421

[14]

10.1111/j.1528-1167.2007.01402.x

[15]

10.1016/s0022-3956(03)00018-9

[16]

McIntosh B "Second‐line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed‐treatment comparison meta‐analysis" Open Med (2011)

[17]

10.1176/appi.ajp.157.6.975

[18]

10.1161/01.hyp.37.2.250

[19]

Centers for Disease Control and Prevention. NHANES questionnaires datasets and related documentation. Accessed April 12 2021.https://wwwn.cdc.gov/nchs/nhanes

[20]

10.1161/01.cir.0000437739.71477.ee

[21]

Korn EL "Confidence intervals for proportions with small expected number of positive counts estimated from survey data" Surv Methodol (1998)

[22]

LumleyT. Survey: Analysis of Complex Survey Samples. Accessed March 22 2021.https://CRAN.R‐project.org/package=survey

[23]

ParkerJD TalihM MalecDJ et al.National Center for Health Statistics data presentation standards for proportions: data evaluation and methods research. Vital and Health Statistics series 2 no. 175. National Center for Health Statistics;2017.

[24]

IngramDD MalecDJ MakucDM et al.National Center for Health Statistics guidelines for analysis of trends: data evaluation and methods research. Vital and Health Statistics series 2 no. 179. National Center for Health Statistics;2018.

[25]

National Cancer Institute. Joinpoint Trend Analysis Software. Accessed November 23 2021.https://surveillance.cancer.gov/joinpoint/

[26]

10.1007/s40618-017-0719-6

[27]

10.1002/oby.20761

[28]

Diabetic Neuropathy: A Position Statement by the American Diabetes Association

Rodica Pop-Busui, Andrew J.M. Boulton, Eva L. Feldman et al.

Diabetes Care 10.2337/dc16-2042

[29]

Overweight, Obesity, and Depression

Floriana S. Luppino, Leonore M. de Wit, Paul F. Bouvy et al.

Archives of General Psychiatry 10.1001/archgenpsychiatry.2010.2

[30]

10.1001/archpsyc.63.7.824

[31]

10.4088/jcp.v60n0402

[32]

10.1002/oby.22507

[33]

10.2337/dc19-s009

[34]

10.1111/j.1751-7176.2009.00119.x

[35]

Saunders KH "Drug‐induced weight gain: rethinking our choices" J Fam Pract (2016)

[36]

Medications that cause weight gain and alternatives in Canada: a narrative review

Sean Wharton, Lilian Raiber, Kristin Serodio et al.

Diabetes, Metabolic Syndrome and Obesity: Targets... 10.2147/dmso.s171365

[37]

10.1001/jama.2015.1617

[38]

10.1517/14656566.2015.1041505

[39]

10.1001/jama.2021.9486

[40]

10.1093/qjmed/hcm044

[41]

FakhouriTHI MartinCB ChenTC et al.An investigation of nonresponse bias and survey location variability in the 2017–2018 National Health and Nutrition Examination Survey: data evaluation and methods research. Vital and Health Statistics series 2 no. 185. National Center for Health Statistics;2020.

Cited By

28

8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes–2026

Mandeep Bajaj, Rozalina G. McCoy · 2025

Diabetes Care

Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing

Babak J. Orandi, Yiting Li · 2024

Clinical Transplantation

Pharmacotherapy of obesity: an update on the available medications and drugs under investigation

Marlene Chakhtoura, Rachelle Haber · 2023

eClinicalMedicine

Metrics

28

Citations

41

References

Details

Published: Dec 14, 2021
Vol/Issue: 30(1)
Pages: 229-239
License: View

Authors

C

Craig M. Hales

Centers for Disease Control and Prevention National Center for Health Statistics Hyattsville Maryland USA

Q

Qiuping Gu

Centers for Disease Control and Prevention National Center for Health Statistics Hyattsville Maryland USA

C

Cynthia L. Ogden

Centers for Disease Control and Prevention National Center for Health Statistics Hyattsville Maryland USA

S

Susan Z. Yanovski

National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda Maryland USA

Cite This Article

Craig M. Hales, Qiuping Gu, Cynthia L. Ogden, et al. (2021). Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey. Obesity, 30(1), 229-239. https://doi.org/10.1002/oby.23299

Use of prescription medications associated with weight gain among US adults, 1999‐2018: A nationally representative survey

You May Also Like